Back

GENFIT acquires nangibotide, plans Phase 2 ACLF trial for Q4 2026

Verifying
  • GENFIT acquired nangibotide and plans to study it in ACLF.
  • Nangibotide was tested in more than 400 subjects across four clinical trials.
  • GENFIT plans to start a Phase 2a ACLF study in the fourth quarter of 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.